press release

May 5, 2017

- Company Expects to Present Initial Clinical Results in Early 2016 CAMBRIDGE, Mass. (BUSINESS WIRE) Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), a leading RNAi therapeutics company, announced today that it has initiated a Phase 1 clinical trial with ALN AS1, a subcutaneously administered investigational RNAi therapeutic targeting aminolevulinic acid synthase 1 (ALAS1) for the treatment of ...

press release

May 5, 2017

- Provides Opportunity for Patients who Participate in APOLLO Phase 3 Trial to Receive Patisiran on Ongoing Basis Consistent With Previous Guidance, Company Expects APOLLO, if Positive, to Enable New Drug Application (NDA) Filing in 2017 Timeframe CAMBRIDGE, Mass. (BUSINESS WIRE) Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that it ...

press release

May 5, 2017

- New Interim Data from Ongoing Phase 1 Study in Hemophilia Subjects Demonstrate an up to 86% AT Knockdown and a Re Balancing of Hemostasis with Normalization of Thrombin Generation up to a Mean Increase of 350% and Marked Improvements in Whole Blood Clotting In Exploratory Post Hoc Analysis, Reduced Bleeding Events Associated with AT Knockdown, with ...

press release

May 5, 2017

CAMBRIDGE, Mass. (BUSINESS WIRE) Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that it plans to host and webcast its annual summer series of online "RNAi Roundtables" this July, August, and September. The 2015 series of events will consist of presentations by a mix of Alnylam scientists, clinical collaborators, and ...

press release

May 5, 2017

- Launched "Alnylam 2020" Guidance for Advancement and Commercialization of RNAi Therapeutics Advanced Multiple Clinical Programs and Presented Evidence for Potential Disease Modifying Activity for Patisiran in Familial Amyloidotic Polyneuropathy (FAP) and ALN AT3 in Hemophilia Plans to Present New Clinical Data for ALN AT3 and Initial Clinical Data for ALN CC5 in Oral Presentations at Medical ...

press release

May 5, 2017

- New Paper Documents Safety, Efficacy, and Durability of Subcutaneous Doses of ALN AT3 in Rodent and Non Human Primate (NHP) Models of Hemophilia CAMBRIDGE, Mass. (BUSINESS WIRE) Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today the publication in Nature Medicine of pre clinical results with ALN AT3, an investigational ...

press release

May 5, 2017

- Company Guides that it Plans to Initiate Phase 1/2 Trial in Late 2015 and Report Initial Clinical Results in Early 2016 New Pre Clinical Data with ALN AAT Presented at Digestive Disease Week (DDW) Meeting, Showing Robust Knockdown of Serum AAT of Up to 93% with Monthly Subcutaneous Dosing in Non Human Primates and a Wide ...

press release

May 5, 2017

- A Mean 2.5 Point Decrease in mNIS+7 Endpoint Compares Favorably to 13 to 18 Point Increase Estimated from Analysis of Historical Data Sets, and is Consistent with Therapeutic Hypothesis that Transthyretin (TTR) Knockdown has the Potential to Halt Neuropathy Progression Based on Promising Results, Company Now Plans to Report 18 Month OLE Clinical Data in ...

press release

May 5, 2017

Natural History Study Results Describe an Average Decline of Approximately 140 Meters in 6 Minute Walk Distance (6 MWD) over 18 Months, Further Validating Co Primary Endpoint in ENDEAVOUR Phase 3 Study of Revusiran in FAC CAMBRIDGE, Mass. (BUSINESS WIRE) Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), a leading RNAi therapeutics company, announced today results from a ...

press release

May 5, 2017

- Introduced Pipeline Growth Strategy for RNAi Therapeutics in Three Strategic Therapeutic Areas, or "STArs," and Launched "Alnylam 2020" Guidance for Advancement and Commercialization of RNAi Therapeutics Presented Positive Data from Multiple Clinical Programs, Including Initial Evidence of Potential Disease Modifying Effects with Patisiran and ALN AT3 Advanced Revusiran into ENDEAVOUR Phase 3 Trial and Added Three ...